A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma.
Journal
Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035
Informations de publication
Date de publication:
28 May 2021
28 May 2021
Historique:
received:
20
01
2021
accepted:
01
05
2021
revised:
15
04
2021
entrez:
29
5
2021
pubmed:
30
5
2021
medline:
30
5
2021
Statut:
epublish
Résumé
Malignant pleural mesothelioma (MPM) is an aggressive cancer with treatment limited to Cisplatin and Pemetrexed chemotherapy. Recently, we showed that drugs targeting the BCL-2-regulated apoptosis pathway could kill MPM cell lines in vitro, and control tumor growth in vivo. These studies showed BCL-XL was the dominant pro-survival BCL-2 family member correlating with its high-level expression in cells and patient tumor samples. In this study we show another inhibitor, AZD4320 that targets BCL-XL (and BCL-2), can also potently kill MPM tumor cells in vitro (EC
Identifiants
pubmed: 34050131
doi: 10.1038/s41420-021-00505-0
pii: 10.1038/s41420-021-00505-0
pmc: PMC8163735
doi:
Types de publication
Journal Article
Langues
eng
Pagination
122Subventions
Organisme : Department of Health | National Health and Medical Research Council (NHMRC)
ID : 1157551
Organisme : Department of Health | National Health and Medical Research Council (NHMRC)
ID : 1166447
Organisme : Department of Health | National Health and Medical Research Council (NHMRC)
ID : 1046092
Organisme : Department of Health | National Health and Medical Research Council (NHMRC)
ID : 1157551
Organisme : La Trobe University
ID : N/A
Organisme : Australian Lung Foundation
ID : N/A
Références
Clin Cancer Res. 2017 Sep 15;23(18):5573-5584
pubmed: 28611196
Cancer Discov. 2016 Oct;6(10):1106-1117
pubmed: 27520294
Nat Commun. 2019 Nov 14;10(1):5167
pubmed: 31727888
Lancet Oncol. 2019 Feb;20(2):239-253
pubmed: 30660609
Cell Death Discov. 2020 Oct 31;6(1):114
pubmed: 33298868
Blood. 2019 Jan 3;133(1):7-17
pubmed: 30361262
J Thorac Oncol. 2018 Nov;13(11):1655-1667
pubmed: 30266660
Sci Transl Med. 2015 Mar 18;7(279):279ra40
pubmed: 25787766
Cell Death Dis. 2019 Apr 24;10(5):342
pubmed: 31019203
Cell Death Dis. 2015 Jan 15;6:e1590
pubmed: 25590800
Expert Rev Anticancer Ther. 2021 Apr;21(4):413-424
pubmed: 33238762
N Engl J Med. 2016 Jan 28;374(4):311-22
pubmed: 26639348
Lancet. 2016 Apr 2;387(10026):1405-1414
pubmed: 26719230
Occup Environ Med. 2015 Sep;72(9):648-55
pubmed: 26045315
Nature. 2016 Oct 27;538(7626):477-482
pubmed: 27760111
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
N Engl J Med. 2018 Mar 22;378(12):1107-1120
pubmed: 29562156
Nat Med. 2013 Feb;19(2):202-8
pubmed: 23291630
Clin Cancer Res. 2012 Jun 1;18(11):3163-9
pubmed: 22496272
Invest New Drugs. 2019 Apr;37(2):210-222
pubmed: 29931583
Clin Cancer Res. 2020 Dec 15;26(24):6535-6549
pubmed: 32988967
Int J Radiat Oncol Biol Phys. 2020 Mar 15;106(4):867-877
pubmed: 31786278
Blood. 2020 Jun 11;135(24):2137-2145
pubmed: 32219442
Clin Respir J. 2018 Jun;12(6):2090-2100
pubmed: 29424961
Commun Biol. 2021 Jan 25;4(1):112
pubmed: 33495510
J Clin Oncol. 2003 Jul 15;21(14):2636-44
pubmed: 12860938
Nat Commun. 2018 Aug 29;9(1):3513
pubmed: 30158527
Cancer Res. 2008 May 1;68(9):3421-8
pubmed: 18451170
Oncogene. 2018 Aug;37(32):4475-4488
pubmed: 29743589
Cancer Cell. 2018 Dec 10;34(6):879-891
pubmed: 30537511
Nat Commun. 2019 Nov 14;10(1):5157
pubmed: 31727958
Nat Commun. 2018 Dec 17;9(1):5341
pubmed: 30559424
Bioinformatics. 2016 Sep 15;32(18):2866-8
pubmed: 27153664
Cancer Discov. 2019 Mar;9(3):354-369
pubmed: 30518523